ACB vs. NRIX, ARDX, ANIP, DAWN, RCUS, GYRE, SANA, PRTA, SYRE, and OCUL
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Nurix Therapeutics (NRIX), Ardelyx (ARDX), ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Arcus Biosciences (RCUS), Gyre Therapeutics (GYRE), Sana Biotechnology (SANA), Prothena (PRTA), Spyre Therapeutics (SYRE), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Nurix Therapeutics (NASDAQ:NRIX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
Nurix Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
Nurix Therapeutics currently has a consensus target price of $25.82, suggesting a potential upside of 17.68%. Given Aurora Cannabis' higher possible upside, equities research analysts clearly believe Nurix Therapeutics is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of -26.97% compared to Aurora Cannabis' net margin of -264.84%. Nurix Therapeutics' return on equity of -9.34% beat Aurora Cannabis' return on equity.
Aurora Cannabis received 322 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 74.68% of users gave Nurix Therapeutics an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
Aurora Cannabis has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
47.6% of Aurora Cannabis shares are held by institutional investors. 7.2% of Nurix Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Nurix Therapeutics and Nurix Therapeutics both had 5 articles in the media. Aurora Cannabis' average media sentiment score of 0.92 beat Nurix Therapeutics' score of 0.14 indicating that Nurix Therapeutics is being referred to more favorably in the media.
Summary
Aurora Cannabis beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
